The Apex Times
Above the Noise
Business Wire
BusinessUnitedHealth reports a sharp jump in earnings, betting on cost control and Optum momentumThe Apex TimesBusinessTesla tells customers it expects to begin selling Cybercabs by year-end as federal review continuesThe Apex TimesBusinessMeta’s Q3 Results Spotlight Key Metrics as Investors Focus Beyond Revenue and EPSThe Apex TimesBusinessCathie Wood’s Ark trimmed Alphabet exposure while adding Rocket Lab after Neutron delay, pointing to a shifting bet on AI-linked outcomesThe Apex TimesBusinessBlackRock’s DVY Outpaced JEPI on Total Returns Over Five Years, a Recent ETF Comparison FindsThe Apex TimesBusinessTesla shares swing after earnings as capex outlook falls to $20 billion and Optimus timeline gets temperedThe Apex TimesBusinessTesla executives told investors demand outpaced production in Q3, citing Full Self-Driving, energy storage and early Robotaxi operationsThe Apex TimesBusinessApple set to hold another October event on Oct. 28, investors’ attention turns to what comes nextThe Apex TimesBusinessMeta looks to fund its wide-ranging AI buildout with a newly created class of stockThe Apex TimesBusinessNetflix shares slide to a 26-month low after a softer Q4 outlook, even as revenue hits a recordThe Apex TimesBusinessAlibaba’s valuation discount runs into geopolitics, while Walmart’s cash machine commands a premium, in a 2026 retail comparisonThe Apex TimesBusinessNetflix outlines another price increase while members continue paying more, CEO remarks raise expectationsThe Apex TimesBusinessUnitedHealth reports a sharp jump in earnings, betting on cost control and Optum momentumThe Apex TimesBusinessTesla tells customers it expects to begin selling Cybercabs by year-end as federal review continuesThe Apex TimesBusinessMeta’s Q3 Results Spotlight Key Metrics as Investors Focus Beyond Revenue and EPSThe Apex TimesBusinessCathie Wood’s Ark trimmed Alphabet exposure while adding Rocket Lab after Neutron delay, pointing to a shifting bet on AI-linked outcomesThe Apex TimesBusinessBlackRock’s DVY Outpaced JEPI on Total Returns Over Five Years, a Recent ETF Comparison FindsThe Apex TimesBusinessTesla shares swing after earnings as capex outlook falls to $20 billion and Optimus timeline gets temperedThe Apex TimesBusinessTesla executives told investors demand outpaced production in Q3, citing Full Self-Driving, energy storage and early Robotaxi operationsThe Apex TimesBusinessApple set to hold another October event on Oct. 28, investors’ attention turns to what comes nextThe Apex TimesBusinessMeta looks to fund its wide-ranging AI buildout with a newly created class of stockThe Apex TimesBusinessNetflix shares slide to a 26-month low after a softer Q4 outlook, even as revenue hits a recordThe Apex TimesBusinessAlibaba’s valuation discount runs into geopolitics, while Walmart’s cash machine commands a premium, in a 2026 retail comparisonThe Apex TimesBusinessNetflix outlines another price increase while members continue paying more, CEO remarks raise expectationsThe Apex TimesBusinessUnitedHealth reports a sharp jump in earnings, betting on cost control and Optum momentumThe Apex TimesBusinessTesla tells customers it expects to begin selling Cybercabs by year-end as federal review continuesThe Apex TimesBusinessMeta’s Q3 Results Spotlight Key Metrics as Investors Focus Beyond Revenue and EPSThe Apex TimesBusinessCathie Wood’s Ark trimmed Alphabet exposure while adding Rocket Lab after Neutron delay, pointing to a shifting bet on AI-linked outcomesThe Apex TimesBusinessBlackRock’s DVY Outpaced JEPI on Total Returns Over Five Years, a Recent ETF Comparison FindsThe Apex TimesBusinessTesla shares swing after earnings as capex outlook falls to $20 billion and Optimus timeline gets temperedThe Apex TimesBusinessTesla executives told investors demand outpaced production in Q3, citing Full Self-Driving, energy storage and early Robotaxi operationsThe Apex TimesBusinessApple set to hold another October event on Oct. 28, investors’ attention turns to what comes nextThe Apex TimesBusinessMeta looks to fund its wide-ranging AI buildout with a newly created class of stockThe Apex TimesBusinessNetflix shares slide to a 26-month low after a softer Q4 outlook, even as revenue hits a recordThe Apex TimesBusinessAlibaba’s valuation discount runs into geopolitics, while Walmart’s cash machine commands a premium, in a 2026 retail comparisonThe Apex TimesBusinessNetflix outlines another price increase while members continue paying more, CEO remarks raise expectationsThe Apex TimesBusinessUnitedHealth reports a sharp jump in earnings, betting on cost control and Optum momentumThe Apex TimesBusinessTesla tells customers it expects to begin selling Cybercabs by year-end as federal review continuesThe Apex TimesBusinessMeta’s Q3 Results Spotlight Key Metrics as Investors Focus Beyond Revenue and EPSThe Apex TimesBusinessCathie Wood’s Ark trimmed Alphabet exposure while adding Rocket Lab after Neutron delay, pointing to a shifting bet on AI-linked outcomesThe Apex TimesBusinessBlackRock’s DVY Outpaced JEPI on Total Returns Over Five Years, a Recent ETF Comparison FindsThe Apex TimesBusinessTesla shares swing after earnings as capex outlook falls to $20 billion and Optimus timeline gets temperedThe Apex TimesBusinessTesla executives told investors demand outpaced production in Q3, citing Full Self-Driving, energy storage and early Robotaxi operationsThe Apex TimesBusinessApple set to hold another October event on Oct. 28, investors’ attention turns to what comes nextThe Apex TimesBusinessMeta looks to fund its wide-ranging AI buildout with a newly created class of stockThe Apex TimesBusinessNetflix shares slide to a 26-month low after a softer Q4 outlook, even as revenue hits a recordThe Apex TimesBusinessAlibaba’s valuation discount runs into geopolitics, while Walmart’s cash machine commands a premium, in a 2026 retail comparisonThe Apex TimesBusinessNetflix outlines another price increase while members continue paying more, CEO remarks raise expectationsThe Apex Times
Back to front
Eli Lilly’s first-quarter results underscore how branded pharma is betting on GLP-1 momentum and pipeline breadth
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 8, 5:08 AM EDT

Eli Lilly’s first-quarter results underscore how branded pharma is betting on GLP-1 momentum and pipeline breadth

Lilly reported a 56% jump in first-quarter revenue and raised its full-year outlook, as the company also announced a key FDA approval for its oral GLP-1 and highlighted progress in multiple late-stage programs.

By The Apex Times Newsroom4 min readAI-assisted Apex article

Eli Lilly’s first-quarter earnings, released April 30, helped set the tone for parts of the branded pharmaceutical sector as investors worked through another round of results. Lilly said revenue rose 56% to $19.8 billion, driven primarily by volume growth in its key marketed medicines, including the company’s GLP-1 portfolio for metabolic disease. In its earnings materials, the company tied the quarter’s performance to continued demand for Mounjaro and Zepbound, while acknowledging realized pricing pressures that partially offset the sales gains.

Along with the revenue increase, Lilly posted a sharp jump in earnings per share. Reported EPS climbed 170% to $8.26, while non-GAAP EPS increased 156% to $8.55. Lilly’s filings also show that both reported and non-GAAP results included acquired in-process research and development (IPR&D) charges, a type of accounting cost tied to past business development deals. By earnings-season standards, the company framed the quarter as a strong start to 2026 and emphasized that it was lifting guidance rather than merely meeting expectations.

Lilly raised its full-year guidance for 2026 as well. It updated revenue expectations to a range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00. Management said the guidance increase reflected stronger underlying business performance in the first quarter. In the same materials, the company pointed to the mix of growth drivers, including volume expansion, and noted that lower realized prices remained a recurring factor in reported results.

A central operating catalyst in Lilly’s quarter was regulatory progress tied to oral GLP-1 treatment. Lilly said the U.S. Food and Drug Administration approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. In Lilly’s description, Foundayo is the only approved GLP-1 pill for weight loss that can be taken any time of day without food and water restrictions, which the company said could widen access compared with older dosing requirements in the class.

Beyond the GLP-1 launch milestone, Lilly also highlighted multiple late-stage clinical updates across therapeutic areas. The company cited positive Phase 3 results for Foundayo in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk, and it referenced progress involving Jaypirca in combination with venetoclax and rituximab for certain relapsed or refractory blood cancers. Lilly also discussed treatment combinations that include Taltz and Zepbound for adults with psoriasis alongside obesity or overweight, and it pointed to retatrutide as a Phase 3 program in type 2 diabetes.

On the business-development side, Lilly said it entered agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics. The company did not characterize in these materials the expected financial impact of each deal at the time of reporting, but it described the acquisitions as part of an ongoing effort to invest in future growth while it continues scaling its marketed portfolio.

For branded pharmaceutical investors, the immediate takeaway is that Lilly is presenting a double-track earnings narrative: near-term sales momentum tied to volume, and longer-duration optionality from pipeline programs. The quarter also illustrates a pattern that has increasingly mattered in the sector’s earnings discussions, where demand growth can lift results even as pricing or realized-price dynamics remain a headwind.

Still, some items remain less clear in what Lilly disclosed publicly in the earnings materials. The company did not break out, in the press-release-style financial summary, how quickly Foundayo uptake will translate into incremental revenue, and it did not provide full detail on timing for additional approvals or how each acquisition will affect future cost structure. Also, while the Yahoo Finance roundup that flagged Lilly as a “leader” in branded pharmaceutical results is part of this editorial context, the exact comparison of “exciting” versus “less so” outcomes across other companies was not directly accessible for verification during this review due to access restrictions.

What to watch next includes Lilly’s rollout plans and any early prescribing and coverage indicates for Foundayo, additional clinical readouts as the company advances Phase 3 programs, and how the market interprets the relationship between volume growth and realized-price declines in subsequent quarters. For the broader branded pharma group, Lilly’s raised guidance may also set a reference point for whether peers can match growth without relying solely on GLP-1 demand.

Why It Matters

  • Lilly’s raised guidance and GLP-1-related regulatory milestone can influence investor expectations for how quickly oral options expand the appetite for weight-loss and metabolic therapies.
  • The quarter highlights how branded pharma earnings performance increasingly depends on volume growth, even when realized pricing pressure persists.
  • Pipeline breadth across obesity, diabetes, immunology, and oncology can affect how investors discount longer-term risk for branded drugmakers.
  • New acquisitions suggest Lilly is positioning for future growth while its blockbuster portfolio continues to carry near-term results.

Sources

Key Facts

  • Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56% year over year.
  • Lilly said first-quarter reported EPS was $8.26, up 170%, and non-GAAP EPS was $8.55, up 156%.
  • Lilly raised its full-year 2026 revenue guidance to $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00.
  • Lilly said the FDA approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems, describing it as an oral GLP-1 pill that can be taken any time of day without food or water restrictions.
  • In a financial summary of the quarter, Lilly reported that worldwide volume growth drove the sales increase, while realized prices declined and partially offset gains.
  • Lilly cited multiple late-stage clinical updates, including Phase 3 results for Foundayo in type 2 diabetes with obesity or overweight at increased cardiovascular risk.
  • Lilly said it agreed to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics.

Healthcare Related

Eli Lilly’s first-quarter results underscore how branded pharma is betting on GLP-1 momentum and pipeline breadth | The Apex Times